X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Injectafer
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
The U.S FDA has approved a single 1000 mg dose option of Injectafer®, ferric carboxymaltose injection, an iron replacement product, for iron deficiency anemia patients who have intolerance to oral iron, have low response to oral iron, or have non-dialysis dependent CKD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Roxadustat
Therapeutic Area: Hematology Product Name: Evrenzo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: FibroGen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
The MHLW approval of EVRENZO marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human Fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: TachoSil
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Corza
Deal Size: $427.0 million Upfront Cash: 427.0 million
Deal Type: Divestment September 16, 2020
Details:
Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human fibrinogen,Thrombin
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 10, 2020
Details:
In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
